Dihydropyrimidine derivatives as MDM2 inhibitors

Area of Science:

• Medicinal Chemistry
• Computational Drug Design
• Cancer Biology

Background:

• MDM2 protein is a key regulator of p53 levels, inhibiting its tumor-suppressive functions.
• Cancer cells often overproduce MDM2, necessitating strategies to disrupt the MDM2-p53 interaction.
• Inhibiting MDM2 offers a promising therapeutic avenue for reactivating p53 in tumors.

Purpose of the Study:

• To design and evaluate Monastrol derivatives as novel inhibitors of MDM2.
• To assess the in silico and in vitro efficacy of these derivatives in cancer cells.
• To explore the potential of the Monastrol scaffold for MDM2 inhibition in cancer therapy.

Main Methods:

• In silico design and virtual screening of Monastrol derivatives.
• Molecular docking, including single-docking, docking with explicit waters, and molecular dynamics (MD) simulations.
• In vitro synthesis of selected compounds and cytotoxicity evaluation using MTT assays on MFC-7 and MDA-MB-231 cell lines.

Main Results:

• Compound 5d demonstrated the best binding affinity (ΔG_ave = -10.35 kcal/mol) in silico.
• MD simulations indicated median potency comparable to Nutlin-3a.
• In vitro MTT assays confirmed the in silico findings, with compound 5d exhibiting an IC₅₀ of 60.09 μM against MCF-7 cells.

Conclusions:

• Monastrol derivatives can be repurposed as effective MDM2 inhibitors.
• Compound 5d shows significant potential as an anti-cancer agent by inhibiting MDM2 and reactivating p53.
• Further research into these Monastrol-derived MDM2 inhibitors is warranted for future cancer therapy development.